Letters to the Editor

Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma

Clinic of Hematology, Oncology, Stem Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany; Cologne Lymphoma Working Group (CLWG), Cologne
Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg
Clinic of Hematology, Oncology, Stem Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart
Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg
Stuttgart Cancer Center – Tumorzentrum Eva Mayr-Stihl, Stuttgart
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany; Cologne Lymphoma Working Group (CLWG), Cologne
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany; Cologne Lymphoma Working Group (CLWG), Cologne, Germany; Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf (MSSO ABCD), Cologne, Faculty of Medicine and University Hospital of Cologne, D-50937, Cologne
Clinic of Hematology, Oncology, Stem Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart
Department of Medicine I, Medical Center, Faculty of Medicine, University of Freiburg
Haematologica Early view Jan 23, 2025 https://doi.org/10.3324/haematol.2024.286347